Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Immunologic adjuvant and vaccine containing immunologic adjuvant

An immune adjuvant and immune vaccine technology, which is applied in the field of immune adjuvants and vaccines containing the immune adjuvant, can solve the problems of flocculation, poor adjuvant stability, unfavorable production and practical application, etc.

Inactive Publication Date: 2014-12-24
LANZHOU UNIVERSITY
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the adjuvant has poor stability and is prone to flocculation, which is not conducive to the final production and practical application.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunologic adjuvant and vaccine containing immunologic adjuvant
  • Immunologic adjuvant and vaccine containing immunologic adjuvant
  • Immunologic adjuvant and vaccine containing immunologic adjuvant

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] Preparation and performance verification of immune adjuvant and immune vaccine of the present invention

[0082] 1. Adjuvant DDA and PolyI:C adjuvant screening

[0083] DDA is a cationic liposome, which self-assembles into a liposome when the temperature is heated to a gel liquid higher than its phase transition temperature, and the liposome in the complex cationic gel state and the oppositely charged polymyocyte PolyI:C usually Lead to high instability, easy to form flocculation phenomenon. This patent improves the stability of the adjuvant DDA and PolyI:C by adding different auxiliary materials to stabilize the adjuvant DDA and PolyI:C.

[0084]In the selection of different excipients, we selected excipients such as Tween 80, Span 85, gelatin, cholesterol, lecithin, β-cyclodextrin, PLGA and other excipients, and tested their effect on the particle size and Zeta potential. Improved effect of adjuvants DDA and PolyI:C. The liposomes formed by adding different adjuvan...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an immunologic adjuvant. The immunologic adjuvant is composed of cationic liposome dimethyl trihexadecyl alkylammonium (DDA), PolyI: C and cholesterol. According to the immunologic adjuvant provided by the invention, a novel vaccine adjuvant DDA+PolyI: C+cholesterol (DPC for short) is constructed by combining cholesterol with DDA and polyI: C through screening reagents capable of enhancing the stability of the adjuvants and giving consideration to both immunocompetence and clinical application of a vaccine, thus improving the stabilities of the adjuvants DDA and polyI: C, and the particle size is less than that of DDA+PolyI: C (DP for short), thus facilitating the performances of later-period development and production; the immunologic adjuvant is combined with fusion protein LT70 to construct a tuberculosis subunit vaccine LT-70-DPC, and the overall protection effect is found to be higher than those of BCG and LT70-DP.

Description

technical field [0001] The invention relates to an immune adjuvant and a vaccine containing the immune adjuvant. Background technique [0002] Aluminum adjuvant, as the only registered adjuvant, is widely used in the world. It mainly mediates humoral immunity, but it is not effective for diseases mainly based on cellular immunity. The co-infection of Mycobacterium tuberculosis and human immunodeficiency virus has become a global public health problem. Both diseases are characterized by cellular immunity, and currently there is a lack of ideal adjuvants for cellular immunity. In recent years, although adjuvant research has made great progress, due to safety considerations, few new vaccine adjuvants have been approved. It is extremely urgent to develop new adjuvants that are safe and can effectively induce humoral immunity and cellular immunity. [0003] Cationic liposomes have been discovered as vaccine adjuvants for more than 40 years. They not only present antigens and pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K39/04A61P31/06
Inventor 祝秉东刘勋汪月何珊珊牛红霞马澜何娟娟陆小铃于红娟
Owner LANZHOU UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com